-
-
-
-
-
-
-
Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China
-
-
-
-
-
-
-
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-line Treatment of Advanced or Metastatic Gastric or Gastroeso
-
-
-
-
-
-
66,591 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

